Insider Purchases: Market participants have noted significant open-market acquisitions by a major shareholder totaling over $1.8 million. This development has fueled conversations regarding potential strategic positioning within the biotech sector. Observers highlight the timing amid broader trading activity.
Trading Momentum: The stock registered a double-digit percentage increase with elevated volume levels exceeding 3 million shares. Discussions center on the implications for short-term price action and sector rotation. Analysts on social media emphasize the need for sustained follow-through in subsequent sessions.
Catalyst Outlook: Recent updates on clinical trial advancements have drawn attention to mid-term prospects. Participants weigh these factors against historical volatility in the space. Overall engagement reflects measured interest in upcoming milestones.
Note: This discussion summary was generated from an AI condensation of post data.
Tenax Therapeutics Insider Trading Activity
Tenax Therapeutics insiders have traded $TENX stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TENX stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, LLC ADAR1 has made 3 purchases buying 1,025,867 shares for an estimated $1,814,147 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Tenax Therapeutics Hedge Fund Activity
We have seen 80 institutional investors add shares of Tenax Therapeutics stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 3,619,773 shares (+1122.1%) to their portfolio in Q2 2026, for an estimated $52,667,697
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,343,456 shares (-79.4%) from their portfolio in Q2 2026, for an estimated $34,097,284
- VIVO CAPITAL, LLC added 2,291,667 shares (+1100.0%) to their portfolio in Q2 2026, for an estimated $33,343,754
- BLACKROCK, INC. added 1,711,011 shares (+10078.4%) to their portfolio in Q2 2026, for an estimated $24,895,210
- VENROCK ADVISER, LLC removed 1,675,262 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $24,375,062
- STONEPINE CAPITAL MANAGEMENT, LLC added 963,316 shares (+8106.0%) to their portfolio in Q1 2026, for an estimated $15,403,422
- CANDRIAM S.C.A. added 749,588 shares (+inf%) to their portfolio in Q2 2026, for an estimated $10,906,505
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Tenax Therapeutics Price Targets
Multiple analysts have issued price targets for $TENX recently. We have seen 4 analysts offer price targets for $TENX in the last 6 months, with a median target of $37.5.
Here are some recent targets:
- Gautam Chukka from Chardan Capital set a target price of $27.0 on 07/02/2026
- Olivia Brayer Saunders from Cantor Fitzgerald set a target price of $35.0 on 06/24/2026
- Seamus Fernandez from Guggenheim set a target price of $40.0 on 06/22/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $50.0 on 06/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
